PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT • 2.1 Preface • 2.2 Preface • 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 04: PIPELINE ANALYSIS PART 05: MARKET SIZING • Market definition • Market sizing 2018 • Market size and forecast 2018-2023 PART 06: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 07: MARKET SEGMENTATION BY PRODUCT • Market segmentation by product • Comparison by product • Combination therapy - Market size and forecast 2018-2023 • Monotherapy - Market size and forecast 2018-2023 • Market opportunity by product PART 08: CUSTOMER LANDSCAPE PART 09: MARKET SEGMENTATION BY TYPE • Chronic bronchitis • Emphysema PART 10: GEOGRAPHIC LANDSCAPE • Geographic segmentation • Geographic comparison • North America - Market size and forecast 2018-2023 • Europe - Market size and forecast 2018-2023 • Asia - Market size and forecast 2018-2023 • ROW - Market size and forecast 2018-2023 • Key leading countries • Market opportunity PART 11: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 12: MARKET TRENDS PART 13: VENDOR LANDSCAPE • Overview • Landscape disruption PART 14: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • AstraZeneca • Boehringer Ingelheim • GlaxoSmithKline • Novartis • Teva Pharmaceutical PART 15: APPENDIX • Research methodology • List of abbreviations   Exhibit 01: Years in consideration Exhibit 02: Global respiratory disorder drugs market Exhibit 03: Segments of global respiratory disorder drugs market Exhibit 04: Market characteristics Exhibit 05: Market segments Exhibit 06: Pipeline molecules for COPD Exhibit 07: Market definition - Inclusions and exclusions checklist Exhibit 08: Market size 2018 Exhibit 09: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 10: Global market: Year-over-year growth 2019-2023 (%) Exhibit 11: Five forces analysis 2018 Exhibit 12: Five forces analysis 2023 Exhibit 13: Bargaining power of buyers Exhibit 14: Bargaining power of suppliers Exhibit 15: Threat of new entrants Exhibit 16: Threat of substitutes Exhibit 17: Threat of rivalry Exhibit 18: Market condition - Five forces 2018 Exhibit 19: Product - Market share 2018-2023 (%) Exhibit 20: Comparison by product Exhibit 21: Combination therapy - Market size and forecast 2018-2023 ($ millions) Exhibit 22: Combination therapy - Year-over-year growth 2019-2023 (%) Exhibit 23: Monotherapy - Market size and forecast 2018-2023 ($ millions) Exhibit 24: Monotherapy - Year-over-year growth 2019-2023 (%) Exhibit 25: Sales of monotherapy drugs 2015-2017 ($ millions) Exhibit 26: Market opportunity by product Exhibit 27: Customer landscape Exhibit 28: Market share by geography 2018-2023 (%) Exhibit 29: Geographic comparison Exhibit 30: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 31: North America - Year-over-year growth 2019-2023 (%) Exhibit 32: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 33: Europe - Year-over-year growth 2019-2023 (%) Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 35: Asia - Year-over-year growth 2019-2023 (%) Exhibit 36: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 37: ROW - Year-over-year growth 2019-2023 (%) Exhibit 38: Key leading countries Exhibit 39: Market opportunity Exhibit 40: Decision framework Exhibit 41: Mechanism of action of budesonide/ glycopyrronium/formoterol triple combination Exhibit 42: New drug approvals for COPD Exhibit 43: US FDA-approved fixed-dose combination LABAs and LAMAs Exhibit 44: Impact of drivers and challenges Exhibit 45: Examples of advanced nebulizers Exhibit 46: Vendor landscape Exhibit 47: Landscape disruption Exhibit 48: Vendors covered Exhibit 49: Vendor classification Exhibit 50: Market positioning of vendors Exhibit 51: AstraZeneca - Vendor overview Exhibit 52: AstraZeneca - Business segments Exhibit 53: AstraZeneca - Organizational developments Exhibit 54: AstraZeneca - Geographic focus Exhibit 55: AstraZeneca - Key offerings Exhibit 56: Boehringer Ingelheim - Vendor overview Exhibit 57: Boehringer Ingelheim - Business segments Exhibit 58: Boehringer Ingelheim - Organizational developments Exhibit 59: Boehringer Ingelheim - Geographic focus Exhibit 60: Boehringer Ingelheim - Segment focus Exhibit 61: Boehringer Ingelheim - Key offerings Exhibit 62: GlaxoSmithKline - Vendor overview Exhibit 63: GlaxoSmithKline - Business segments Exhibit 64: GlaxoSmithKline - Organizational developments Exhibit 65: GlaxoSmithKline - Geographic focus Exhibit 66: GlaxoSmithKline - Segment focus Exhibit 67: GlaxoSmithKline - Key offerings Exhibit 68: Novartis - Vendor overview Exhibit 69: Novartis - Business segments Exhibit 70: Novartis - Organizational developments Exhibit 71: Novartis - Geographic focus Exhibit 72: Novartis - Segment focus Exhibit 73: Novartis - Key offerings Exhibit 74: Teva Pharmaceutical - Vendor overview Exhibit 75: Teva Pharmaceutical - Business segments Exhibit 76: Teva Pharmaceutical - Organizational developments Exhibit 77: Teva Pharmaceutical - Geographic focus Exhibit 78: Teva Pharmaceutical - Segment focus Exhibit 79: Teva Pharmaceutical - Key offerings Exhibit 80: Validation techniques employed for market sizing Exhibit 81: List of abbreviations  

AstraZeneca Boehringer Ingelheim GlaxoSmithKline Novartis Teva Pharmaceutical